LeMaitre Vascular (LMAT) PT Lowered to $32.00 at Canaccord Genuity

LeMaitre Vascular (NASDAQ:LMAT) had its target price lowered by Canaccord Genuity from $40.00 to $32.00 in a research note issued to investors on Monday morning, The Fly reports. Canaccord Genuity currently has a hold rating on the medical instruments supplier’s stock.

LMAT has been the topic of several other reports. ValuEngine downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research report on Thursday, June 21st. BidaskClub downgraded shares of LeMaitre Vascular from a buy rating to a hold rating in a research report on Friday, June 22nd. Zacks Investment Research downgraded shares of LeMaitre Vascular from a hold rating to a sell rating in a research report on Wednesday, September 26th. Lake Street Capital began coverage on shares of LeMaitre Vascular in a research report on Monday, June 25th. They set a buy rating and a $45.00 price objective on the stock. Finally, Roth Capital downgraded shares of LeMaitre Vascular from a buy rating to a neutral rating and raised their price objective for the stock from $38.00 to $39.00 in a research report on Tuesday, October 2nd. One research analyst has rated the stock with a sell rating, five have assigned a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of Hold and an average price target of $35.63.

NASDAQ LMAT opened at $28.41 on Monday. The firm has a market capitalization of $748.16 million, a P/E ratio of 33.03, a P/E/G ratio of 2.42 and a beta of 0.63. LeMaitre Vascular has a 12 month low of $26.99 and a 12 month high of $41.28.

LeMaitre Vascular (NASDAQ:LMAT) last posted its earnings results on Friday, October 5th. The medical instruments supplier reported $0.21 EPS for the quarter, meeting the Zacks’ consensus estimate of $0.21. LeMaitre Vascular had a net margin of 21.09% and a return on equity of 19.49%. The firm had revenue of $24.17 million for the quarter, compared to the consensus estimate of $26.06 million. As a group, research analysts predict that LeMaitre Vascular will post 1.07 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, December 6th. Shareholders of record on Tuesday, November 20th will be given a dividend of $0.07 per share. This represents a $0.28 annualized dividend and a yield of 0.99%. The ex-dividend date of this dividend is Monday, November 19th. LeMaitre Vascular’s payout ratio is currently 32.56%.

In other news, Chairman George W. Lemaitre sold 39,820 shares of the firm’s stock in a transaction on Friday, July 27th. The shares were sold at an average price of $37.34, for a total value of $1,486,878.80. Following the completion of the sale, the chairman now owns 3,085,291 shares in the company, valued at approximately $115,204,765.94. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO George W. Lemaitre sold 22,000 shares of the firm’s stock in a transaction on Wednesday, July 25th. The stock was sold at an average price of $37.26, for a total transaction of $819,720.00. Following the completion of the sale, the chief executive officer now owns 3,085,291 shares of the company’s stock, valued at approximately $114,957,942.66. The disclosure for this sale can be found here. Insiders have sold a total of 97,506 shares of company stock worth $3,608,759 over the last three months. 20.30% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. BlackRock Inc. lifted its stake in shares of LeMaitre Vascular by 4.0% in the 2nd quarter. BlackRock Inc. now owns 2,425,454 shares of the medical instruments supplier’s stock worth $81,202,000 after acquiring an additional 93,615 shares during the period. Conestoga Capital Advisors LLC lifted its stake in shares of LeMaitre Vascular by 8.9% in the 2nd quarter. Conestoga Capital Advisors LLC now owns 1,392,591 shares of the medical instruments supplier’s stock worth $46,624,000 after acquiring an additional 113,705 shares during the period. Dimensional Fund Advisors LP lifted its stake in shares of LeMaitre Vascular by 0.3% in the 2nd quarter. Dimensional Fund Advisors LP now owns 1,006,078 shares of the medical instruments supplier’s stock worth $33,684,000 after acquiring an additional 2,824 shares during the period. Epoch Investment Partners Inc. lifted its stake in shares of LeMaitre Vascular by 20.8% in the 2nd quarter. Epoch Investment Partners Inc. now owns 932,093 shares of the medical instruments supplier’s stock worth $31,207,000 after acquiring an additional 160,754 shares during the period. Finally, Janus Henderson Group PLC lifted its stake in shares of LeMaitre Vascular by 14.4% in the 2nd quarter. Janus Henderson Group PLC now owns 691,670 shares of the medical instruments supplier’s stock worth $23,157,000 after acquiring an additional 87,197 shares during the period. Institutional investors own 79.75% of the company’s stock.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc designs, markets, sells, services, and supports medical devices and implants for the treatment of peripheral vascular disease worldwide. The company offers angioscope, a fiber optic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries or veins; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to temporarily perfuse the blood and other fluids into the vasculature.

Featured Article: What does RSI mean?

The Fly

Analyst Recommendations for LeMaitre Vascular (NASDAQ:LMAT)

Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply